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Table S1. Data for various forms of pain reported as serious side effects in the clinical trials 
listed in Table 1. Only data from the six forms of pain discussed in the “Major Pain Events” 
section are listed here.  
Headache 
Clinical trial No. Positive counts in 
experimental group 
Negative counts in 
experimental group 
Positive counts 
in control group 
Negative counts 
in control group 
NCT00558103 1 37 0 13 
NCT00374322 0 1573 1 1573 
NCT00553358 0 152 1 148 
NCT00490139 2 2059 1 2075 
NCT00073528 0 654 2 622 
NCT00390455 2 139 0 137 
NCT00075270 1 292 0 286 
NCT00770809 0 115 1 114 
Arthralgia 
Clinical trial No. Positive counts in 
experimental group 
Negative counts in 
experimental group 
Positive counts 
in control group 
Negative counts 
in control group 
NCT00486954 1 130 0 129 
NCT00490139 1 2060 0 2076 
NCT00073528 2 652 5 619 
NCT00390455 0 141 1 136 
NCT00075270 2 291 0 286 
NCT00680901 0 270 1 266 
Bone pain 
Clinical trial No. Positive counts in 
experimental group 
Negative counts in 
experimental group 
Positive counts 
in control group 
Negative counts 
in control group 
NCT00073528 1 651 1 623 
S2 
 
NCT00390455 0 141 1 136 
NCT00374322 0 1573 1 1573 
NCT00680901 0 270 1 266 
NCT00770809 0 115 1 114 
Myalgia 
Clinical trial No. Positive counts in 
experimental group 
Negative counts in 
experimental group 
Positive counts 
in control group 
Negative counts 
in control group 
NCT00490139 2 2059 0 2076 
NCT00075270 0 293 1 285 
NCT00770809 3 112 2 113 
NCT00374322 0 1573 1 1573 
NCT00424255 1 348 1 335 
Pain in extremity 
Clinical trial No. Positive counts in 
experimental group 
Negative counts in 
experimental group 
Positive counts 
in control group 
Negative counts 
in control group 
NCT00073528 1 653 0 624 
NCT00075270 3 290 0 286 
Musculoskeletal pain 
Clinical trial No. Positive counts in 
experimental group 
Negative counts in 
experimental group 
Positive counts 
in control group 
Negative counts 
in control group 
NCT00073528 1 653 0 624 
     
 
Table S2. Analysis of risks of bias about clinical trials used in this meta-analysis.  

















NCT00486954 O X X O O O 
NCT00387127 O O O O O O 
NCT00558103 O O O O O Xa  
NCT00374322 O O O O O O 
NCT00430781 O X X O O O 
NCT00680901 O O O O O O 
NCT00553358 O X X O O O 
NCT00371566 O O X O O Xa  
NCT00424255 O O O O O O 
NCT00490139 O X X O O O 
NCT00073528 O O O O O O 
NCT00429299 O X X O O O 
NCT00390455 O O O O O O 
NCT00422903 O O O O O O 
S3 
 
NCT00524303 O X X O O O 
NCT00075270 O O O O O O 
NCT00770809 O X X O O O 
NCT00281658 O O O O O O 
NCT00968968 O X X O O O 
NCT01160211 O X X O O O 
  a: Patient number in experimental group and control group are not about equal 
O Low Risk of 
Bias 
     
X High Risk of 
Bias 
     
? Not Enough Information 
    
 
Table S3. Patient counts of different kinds of pain tolled this meta-analysis.  
Pain Type Patient 
Count 
Headache 12661 
Arthralgia  11268 
Myalgia   8420 
Musculoskeletal pain  7664 
Pain in extremity 6887 
Bone pain 6563 
Pharyngolaryngeal pain 3438 
Chest pain 2679 
Neck pain 2191 
Oral pain 1567 
Skin pain 1284 
Toothache  979 
Breast pain 849 
Ear pain 750 
Pain in jaw 579 
Tumor Pain  579 
Groin  Pain  579 
Lymph node pain 579 
Pleuritic pain  579 
Neuralgia  579 
Procedural Pain  197 
Pelvic Pain  150 





Table S4. Drug used in experimental group and control group in the 20 trials analyzed 
Clinical trial # Experimental group Control group 
NCT00486954 Lapatinib + Paclitaxel  Paclitaxel Alone 
NCT00387127 Chemoradiotherapy + Lapatinib, 
Followed by Lapatinib 
Chemoradiotherapy + Placebo, 
Followed by Placebo 
NCT00558103 Lapatinib + Pazopanib  Pazopanib  
NCT00374322 Lapatinib  Placebo 
NCT00430781 Lapatinib + Pazopanib  Pazopanib  
NCT00680901 CapeOx + Lapatinib CapeOx + Placebo 
NCT00553358 Lapatinib + Trastuzumab  Trastuzumab  
NCT00371566 Lapatinib Placebo 
NCT00424255 Lapatinib Placebo 
NCT00490139 Lapatinib + Trastuzumab Trastuzumab 
NCT00073528 Letrozole + Lapatinib  Letrozole + Placebo 
NCT00429299 Chemoradiotherapy + Trastuzumab 
+ Lapatinib  
Chemotherapy + Trastuzumab 
NCT00390455 Lapatinib Placebo 
NCT00422903 Letrozole + Lapatinib Letrozole + Placebo  
NCT00524303 Trastuzumab + Lapatinib Trastuzumab 
NCT00075270 Lapatinib + Paclitaxel Placebo + Paclitaxel 
NCT00770809 Trastuzumab + Paclitaxel + 
Lapatinib 
Trastuzumab + Paclitaxel  
NCT00281658 Lapatinib + Paclitaxel Placebo + Paclitaxel 
NCT00968968 Lapatinib + Trastuzumab Trastuzumab 
NCT01160211 Lapatinib + Trastuzumab + 
Aromatase Inhibitors  



















Figure S2-1. Overall effect of lapatinib treatment on bone pain, arthralgia, and musculoskeletal 
pain. Sizes of data markers are proportional to the amount of data contributed by each trial. OR, 







Pain in Extremity 
 
Figure S2-2. Overall effect of lapatinib treatment on headache and pain in extremity. Sizes of data 








Figure S2-3. Overall effect of lapatinib treatment on myalgia. Sizes of data markers are 
proportional to the amount of data contributed by each trial. OR, odds ratio; CI, confidence 
interval. 
 
Figure S2-4. Overall effect of the lapatinib treatment on various forms of pain. Sizes of data 






Figure S3-1. Funnel plot for headache 
 




Figure S3-3. Funnel plot for arthralgia 
 




Figure S3-5. Funnel plot for pain in extremity 
 









Figure S4-1. Overall pain-relieving effect of lapatinib, grouped by the factor concerning whether 












Figure S4-3. Overall pain-relieving effect of lapatinib, grouped by the dosage of lapatinib used 





Figure S4-4. Overall pain-relieving effect of lapatinib, grouped by the additional components 




Figure S4-5. Overall pain-relieving effect of lapatinib, comparing only the group with paclitaxel 
used and the pure placebo control group. 
 
Figure S5-1. Effect of lapatinib on myalgia, when NCT00075270, NCT00486954, and 





Figure S5-2. Effect of lapatinib on headache, when NCT00075270, NCT00486954, and 
NCT00281658 were excluded.  
 
 
Figure S5-3. Effect of lapatinib on bone pain, when NCT00075270, NCT00486954, and 





Figure S5-4. Effect of lapatinib on arthralgia, when NCT00075270, NCT00486954, and 
NCT00281658 were excluded.  
 
Figure S5-5. Effect of lapatinib on pain in extremity, when NCT00075270, NCT00486954, and 





Figure S5-6. Effect of lapatinib on musculoskeletal pain, when NCT00075270, NCT00486954, 
and NCT00281658 were excluded.  
 
Figure S6. Effects of afatinib on various forms of pain. Data from NCT00656136.1 
 
Formula for Calculation of Odds Ratio (OR):  
 Diseased Healthy 
Exposed DE HE 
Not exposed DN HN 
OR = (DE/HE)/(DN/HN) = (DEHN)/(DNHE) 
For synthesis of the data from multiple trials, the detailed procedure of the random-effects 




1 Miller, V. A. et al. Afatinib versus placebo for patients with advanced, metastatic non-
small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of 
chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.  13, 528-538 (2012). 
2 Veroniki, A. A. et al. Methods to estimate the between-study variance and its uncertainty 
in meta-analysis. Res Synth Methods 7, 55-79, doi:10.1002/jrsm.1164 (2016). 











1. Study eligibility criteria 
Signaling 
questions/Reviews 




































Bone pain Y Y Y Y Y 
Arthralgia Y Y Y Y Y 
Musculoskeletal pain Y Y Y Y Y 
Headache Y Y Y Y Y 
Pain in extremity Y Y Y Y Y 
Myalgia Y Y Y Y Y 
Overall Y Y Y Y Y 
 
 
2. Identification and selection of studies 
Signaling 
questions/Reviews 















































Bone pain Y N Y Y Y 
Category Target question (e.g. overview or guideline) 
Patients/Population(s): Cancer patients 
Intervention(s): Therapy with lapatinib 
Comparator(s): Same therapy to the intervention group except lapatinib 




Arthralgia Y N Y Y Y 
Musculoskeletal pain Y N Y Y Y 
Headache Y N Y Y Y 
Pain in extremity Y N Y Y Y 
Myalgia Y N Y Y Y 
Overall Y N Y Y Y 
 
 
















and readers to 








for use in 
the 
synthesis? 











error in risk 
of bias 
assessment? 
Bone pain Y Y Y Y Y 
Arthralgia Y Y Y Y Y 
Musculoskeletal pain Y Y Y Y Y 
Headache Y Y Y Y Y 
Pain in extremity Y Y Y Y Y 
Myalgia Y Y Y Y Y 
Overall Y Y Y Y Y 
 
 

























































Bone pain Y Y Y Y Y Y 
ROBIS analysis 
 
Arthralgia Y Y Y Y Y Y 
Musculoskeletal 
pain 
Y Y Y Y Y Y 
Headache Y Y Y Y Y Y 
Pain in extremity Y Y Y Y Y Y 
Myalgia Y Y Y Y Y Y 




Risk of bias in the review 
Signaling 
questions/Reviews 
A. Did the 
interpretation of 
findings address all of 
the concerns identified 
in domain 1 to 4 of 
Phase 2? 
B. Was the relevance 
of identified studies to 
the review's research 
question appropriately 
considered? 
C. Did the reviewers 
avoid emphasizing 
results on the basis of 
their statistical 
significance? 
Bone pain Y Y N 
Arthralgia Y Y N 
Musculoskeletal pain Y Y N 
Headache Y Y N 
Pain in extremity Y Y N 
Myalgia Y Y N 
Overall Y Y N 
 
